CD202b pY1102 Antibody, anti-human, REAfinity™
Synonyms: TIE2, TIE-2, p140 TEK
RECOMBINANT
Bioz Star94/100 Bioz rating
1 Citation1 Image
Clone:
REA583 | K93-754
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a size:
Other sizes

Related products for CD202b pY1102 Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-109-399, 130-109-478
Description:
EA-hy 926 cells were serum starved overnight, resuspended in serum-free DMEM, and rested for 20 minutes at 37 °C, and then either left unstimulated (left peak) or stimulated with 1 mM pervanadate for 20 minutes at 37 °C. Cells were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with CD202b pY1102 antibodies and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
Specifications for CD202b pY1102 Antibody, anti-human, REAfinity™
Overview

Clone REA583 recognizes the Y1102-phosphorylated form of CD202b, which is 145 kDa type I transmembrane tyrosine kinase receptor. CD202b is composed of an amino-terminal ligand binding domain with immunoglobulin domains, epithelial growth factor repeats, and fibronectin-like 3 repeats, a single transmembrane domain, and an intracellular tyrosine kinase domain. Expression of CD202b is found on endothelial cells and a subpopulation of monocytes. Angiopoietins are the natural ligands of CD202b. Activation of CD202b dependent signaling pathways are involved in survival and apoptosis of endothelial cells, in controlling vascular permeability, and regulation of the capillary sprouting that occurs during normal angiogenesis.

Additional information: Clone REA583 displays negligible binding to Fc receptors.

Alternative names

TIE2, TIE-2, p140 TEK

Detailed product information

Technical specifications

Clone
REA583
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD202b pY1102
Molecular mass of antigen [kDa]
124
Distribution of antigen
endothelial cells, hematopoietic stem and progenitor cells
Entrez Gene ID
RRID
AB_2656158, AB_2656159

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD202b pY1102 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support